Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clevidipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Clevidipine Butyrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertensive Crisis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 24, 2023
Lead Product(s) : Clevidipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clevidipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies
Details : Clevidipine Butyrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertensive Crisis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Clevidipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clevidipine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF
Details : Clevidipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dyspnea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Clevidipine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable